S&P 500   3,136.28 (+0.01%)
DOW   27,906.86 (-0.01%)
QQQ   204.35 (+0.14%)
AAPL   269.31 (+0.90%)
FB   200.82 (-0.26%)
MSFT   151.48 (+0.08%)
GOOGL   1,343.94 (+0.07%)
AMZN   1,742.09 (-0.42%)
CGC   20.15 (-5.35%)
NVDA   214.78 (+1.23%)
MU   47.80 (+2.91%)
BABA   201.21 (+1.24%)
GE   11.02 (+0.27%)
TSLA   350.19 (+3.14%)
T   38.11 (+0.18%)
AMD   39.55 (+1.59%)
ACB   2.52 (-3.82%)
PRI   135.41 (+0.04%)
NFLX   296.13 (-2.11%)
BAC   33.53 (+0.06%)
GILD   66.91 (-0.03%)
DIS   146.15 (-0.04%)
S&P 500   3,136.28 (+0.01%)
DOW   27,906.86 (-0.01%)
QQQ   204.35 (+0.14%)
AAPL   269.31 (+0.90%)
FB   200.82 (-0.26%)
MSFT   151.48 (+0.08%)
GOOGL   1,343.94 (+0.07%)
AMZN   1,742.09 (-0.42%)
CGC   20.15 (-5.35%)
NVDA   214.78 (+1.23%)
MU   47.80 (+2.91%)
BABA   201.21 (+1.24%)
GE   11.02 (+0.27%)
TSLA   350.19 (+3.14%)
T   38.11 (+0.18%)
AMD   39.55 (+1.59%)
ACB   2.52 (-3.82%)
PRI   135.41 (+0.04%)
NFLX   296.13 (-2.11%)
BAC   33.53 (+0.06%)
GILD   66.91 (-0.03%)
DIS   146.15 (-0.04%)
S&P 500   3,136.28 (+0.01%)
DOW   27,906.86 (-0.01%)
QQQ   204.35 (+0.14%)
AAPL   269.31 (+0.90%)
FB   200.82 (-0.26%)
MSFT   151.48 (+0.08%)
GOOGL   1,343.94 (+0.07%)
AMZN   1,742.09 (-0.42%)
CGC   20.15 (-5.35%)
NVDA   214.78 (+1.23%)
MU   47.80 (+2.91%)
BABA   201.21 (+1.24%)
GE   11.02 (+0.27%)
TSLA   350.19 (+3.14%)
T   38.11 (+0.18%)
AMD   39.55 (+1.59%)
ACB   2.52 (-3.82%)
PRI   135.41 (+0.04%)
NFLX   296.13 (-2.11%)
BAC   33.53 (+0.06%)
GILD   66.91 (-0.03%)
DIS   146.15 (-0.04%)
S&P 500   3,136.28 (+0.01%)
DOW   27,906.86 (-0.01%)
QQQ   204.35 (+0.14%)
AAPL   269.31 (+0.90%)
FB   200.82 (-0.26%)
MSFT   151.48 (+0.08%)
GOOGL   1,343.94 (+0.07%)
AMZN   1,742.09 (-0.42%)
CGC   20.15 (-5.35%)
NVDA   214.78 (+1.23%)
MU   47.80 (+2.91%)
BABA   201.21 (+1.24%)
GE   11.02 (+0.27%)
TSLA   350.19 (+3.14%)
T   38.11 (+0.18%)
AMD   39.55 (+1.59%)
ACB   2.52 (-3.82%)
PRI   135.41 (+0.04%)
NFLX   296.13 (-2.11%)
BAC   33.53 (+0.06%)
GILD   66.91 (-0.03%)
DIS   146.15 (-0.04%)
Log in

NASDAQ:IOVA - Iovance Biotherapeutics Stock Price, Forecast & News

$25.60
-0.02 (-0.08 %)
(As of 12/10/2019 01:46 PM ET)
Today's Range
$25.00
Now: $25.60
$25.87
50-Day Range
$19.57
MA: $22.27
$25.71
52-Week Range
$7.26
Now: $25.60
$26.59
Volume628,302 shs
Average Volume1.20 million shs
Market Capitalization$3.23 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.99
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IOVA
CUSIPN/A
Phone650-260-7120

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.78 per share

Profitability

Net Income$-123,580,000.00

Miscellaneous

Employees88
Market Cap$3.23 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive IOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.


Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics Inc (NASDAQ:IOVA) posted its quarterly earnings results on Monday, November, 4th. The biotechnology company reported ($0.40) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.01. View Iovance Biotherapeutics' Earnings History.

When is Iovance Biotherapeutics' next earnings date?

Iovance Biotherapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Iovance Biotherapeutics.

What price target have analysts set for IOVA?

10 Wall Street analysts have issued twelve-month price objectives for Iovance Biotherapeutics' shares. Their forecasts range from $27.00 to $34.00. On average, they anticipate Iovance Biotherapeutics' stock price to reach $31.10 in the next twelve months. This suggests a possible upside of 21.5% from the stock's current price. View Analyst Price Targets for Iovance Biotherapeutics.

What is the consensus analysts' recommendation for Iovance Biotherapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iovance Biotherapeutics.

What are Wall Street analysts saying about Iovance Biotherapeutics stock?

Here are some recent quotes from research analysts about Iovance Biotherapeutics stock:
  • 1. According to Zacks Investment Research, "Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. " (10/17/2019)
  • 2. HC Wainwright analysts commented, "Our thesis on TILs stands strong. In accordance with our thesis, showing efficacy in solid tumors beyond melanoma continues to represent a game changer for Iovance and, on a broader look, we continue to view this company as a viable takeout candidate for Big Pharma. We would like to reiterate that, apart from academic-based TILs therapies such as NCI and MD Anderson, Iovance is the only biotech that is developing a commercial TIL product to treat a variety of tumors and patients using the predefined cryopreserved 22-day manufacturing strategy." (7/2/2019)
  • 3. Chardan Capital analysts commented, "We therefore expect to see a similar rate in the registration-directed Cohort 4 which is currently enrolling." (5/31/2019)

Has Iovance Biotherapeutics been receiving favorable news coverage?

Press coverage about IOVA stock has trended somewhat positive on Tuesday, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Iovance Biotherapeutics earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Iovance Biotherapeutics.

Are investors shorting Iovance Biotherapeutics?

Iovance Biotherapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 14,790,000 shares, an increase of 5.8% from the October 31st total of 13,980,000 shares. Based on an average daily volume of 1,310,000 shares, the short-interest ratio is currently 11.3 days. Currently, 13.1% of the company's stock are short sold. View Iovance Biotherapeutics' Current Options Chain.

Who are some of Iovance Biotherapeutics' key competitors?

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Portola Pharmaceuticals (PTLA), Applied Materials (AMAT), Immunomedics (IMMU), Kadmon (KDMN), CA (CA), BlackRock (BLK), Seattle Genetics (SGEN), Bristol-Myers Squibb (BMY), Endologix (ELGX) and Lexicon Pharmaceuticals (LXRX).

Who are Iovance Biotherapeutics' key executives?

Iovance Biotherapeutics' management team includes the folowing people:
  • Dr. Maria Fardis, CEO, Pres & Director (Age 51)
  • Mr. Timothy E. Morris, CFO, Principal Accounting Officer, Corp. Sec. & Treasurer (Age 57)
  • Dr. Frederick G. Vogt Ph.D., Esq., Gen. Counsel (Age 45)
  • Mr. Howard B. Johnson, Sr. VP of Corp. Devel., Alliance Management & Program Management (Age 59)
  • Dr. Elma S. Hawkins Ph.D., MBA, Advisor to the Board (Age 62)

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (3.77%), Nikko Asset Management Americas Inc. (1.10%), Sumitomo Mitsui Trust Holdings Inc. (1.10%), Voya Investment Management LLC (0.80%), Point72 Asset Management L.P. (0.62%) and Peregrine Capital Management LLC (0.52%). Company insiders that own Iovance Biotherapeutics stock include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Institutional Ownership Trends for Iovance Biotherapeutics.

Which institutional investors are selling Iovance Biotherapeutics stock?

IOVA stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, SG Americas Securities LLC, Endurant Capital Management LP, Chartwell Investment Partners LLC, Moody Lynn & Lieberson LLC, Squarepoint Ops LLC, Peregrine Capital Management LLC and Mackay Shields LLC. View Insider Buying and Selling for Iovance Biotherapeutics.

Which institutional investors are buying Iovance Biotherapeutics stock?

IOVA stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Voya Investment Management LLC, Point72 Asset Management L.P., Millennium Management LLC, Bailard Inc., State of New Jersey Common Pension Fund D, Sumitomo Mitsui Trust Holdings Inc. and Nikko Asset Management Americas Inc.. Company insiders that have bought Iovance Biotherapeutics stock in the last two years include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Insider Buying and Selling for Iovance Biotherapeutics.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $25.60.

How big of a company is Iovance Biotherapeutics?

Iovance Biotherapeutics has a market capitalization of $3.23 billion. The biotechnology company earns $-123,580,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Iovance Biotherapeutics employs 88 workers across the globe.View Additional Information About Iovance Biotherapeutics.

What is Iovance Biotherapeutics' official website?

The official website for Iovance Biotherapeutics is http://www.iovance.com/.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]


MarketBeat Community Rating for Iovance Biotherapeutics (NASDAQ IOVA)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  430 (Vote Outperform)
Underperform Votes:  228 (Vote Underperform)
Total Votes:  658
MarketBeat's community ratings are surveys of what our community members think about Iovance Biotherapeutics and other stocks. Vote "Outperform" if you believe IOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel